Tiziana Life Sciences Ltd
TLSA
$0.81
$0.00991.24%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -27.27% | -27.27% | -2.51% | -2.51% | 283.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.14% | -25.14% | -7.75% | -7.75% | 92.60% |
| Operating Income | 25.14% | 25.14% | 7.75% | 7.75% | -92.60% |
| Income Before Tax | 7.39% | 7.39% | 20.76% | 20.76% | -90.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.99% | 45.99% | 16.63% | 16.63% | -90.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.99% | 45.99% | 16.63% | 16.63% | -90.94% |
| EBIT | 25.14% | 25.14% | 7.75% | 7.75% | -92.60% |
| EBITDA | 25.20% | 25.20% | 7.78% | 7.76% | -92.72% |
| EPS Basic | 46.32% | 46.32% | 14.67% | 14.67% | -83.04% |
| Normalized Basic EPS | 27.07% | 27.07% | 16.78% | 16.78% | -84.72% |
| EPS Diluted | 46.32% | 46.32% | 14.67% | 14.67% | -83.04% |
| Normalized Diluted EPS | 27.07% | 27.07% | 16.78% | 16.78% | -84.72% |
| Average Basic Shares Outstanding | 0.81% | 0.81% | -2.33% | -2.33% | 4.43% |
| Average Diluted Shares Outstanding | 0.81% | 0.81% | -2.33% | -2.33% | 4.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |